Patents by Inventor Andrew Simon Bell
Andrew Simon Bell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200172543Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.Type: ApplicationFiled: February 10, 2020Publication date: June 4, 2020Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Hidefumi YOSHINAGA, Yohei IKUMA, Junya IKEDA, Satoshi ADACHI, Harunobu MITSUNUMA, Yoshinori AIHARA, Jeremy BESNARD, Andrew Simon BELL
-
Publication number: 20200123158Abstract: The present invention relates to novel compounds and pharmaceutically acceptable salts or solvates thereof which have activity as inhibitors of Schistosoma growth. The invention also relates to pharmaceutical compositions comprising such compounds, salts or solvates and to the use of such compounds as medicaments, in particular in the treatment or prevention of schistosomiasis, also known as bilharzia.Type: ApplicationFiled: January 15, 2018Publication date: April 23, 2020Inventors: John Mark Francis Gardner, Andrew Simon Bell
-
Patent number: 10577363Abstract: The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.Type: GrantFiled: September 9, 2015Date of Patent: March 3, 2020Assignee: EPIZYME, INC.Inventors: Lorna Helen Mitchell, Andrew Simon Bell, Richard Chesworth, Megan Alene Cloonan Foley, Kevin Wayne Kuntz, James Edward John Mills, Michael John Munchhof
-
Publication number: 20180370974Abstract: This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, including protozoan infections (such as malaria and leishmaniasis), viral infections (such as human rhinovirus and HIV), and hyperproliferative disorders (such as B-cell lymphoma).Type: ApplicationFiled: June 29, 2016Publication date: December 27, 2018Applicant: Imperial Innovations LimitedInventors: Andrew Simon Bell, Edward William Tate, Robin John Leatherbarrow, Jennie Ann Hutton, James Antony Brannigan
-
Publication number: 20170362217Abstract: The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.Type: ApplicationFiled: September 9, 2015Publication date: December 21, 2017Applicant: EPIZYME, INC.Inventors: Lorna Helen MITCHELL, Andrew Simon BELL, Richard CHESWORTH, Megan Alene Cloonan FOLEY, Kevin Wayne KUNTZ, James Edward John MILLS, Michael John MUNCHHOF
-
Publication number: 20160355528Abstract: The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.Type: ApplicationFiled: August 19, 2016Publication date: December 8, 2016Applicant: VIIV HEALTHCARE UK LIMITEDInventors: Andrew Simon BELL, Iain Brian GARDNER, Karl Richard GIBSON, David Cameron PRYDE, Florian Michel WAKENHUT
-
Patent number: 9447116Abstract: The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.Type: GrantFiled: July 2, 2014Date of Patent: September 20, 2016Assignee: ViiV Healthcare UK LimitedInventors: Andrew Simon Bell, Iain Brian Gardner, Karl Richard Gibson, David Cameron Pryde, Florian Michel Wakenhut
-
Publication number: 20140315927Abstract: The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Inventors: Andrew Simon Bell, lain Brian GARDNER, Karl Richard GIBSON, David Cameron PRYDE, Florian Michel WAKENHUT
-
Patent number: 8809363Abstract: The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.Type: GrantFiled: November 14, 2011Date of Patent: August 19, 2014Assignee: VIIV Healthcare UK LimitedInventors: Andrew Simon Bell, Iain Brian Gardner, Karl Richard Gibson, David Cameron Pryde, Florian Michel Wakenhut
-
Patent number: 8772343Abstract: The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula 10 (I):(I) or a pharmaceutically acceptable salt thereof, wherein Z, R1, R2, R3, R4 and R5 are as defined in the description. Nav1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.Type: GrantFiled: July 6, 2011Date of Patent: July 8, 2014Assignee: Pfizer LimitedInventors: Andrew Simon Bell, Alan Daniel Brown, Russell Andrew Lewthwaite, Manuel Perez-Pacheco, David James Rawson, Robert Ian Storer, Nigel Alan Swain
-
Patent number: 8685977Abstract: The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein Ar1, X, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.Type: GrantFiled: July 11, 2011Date of Patent: April 1, 2014Assignee: Pfizer LimitedInventors: Andrew Simon Bell, Alan Daniel Brown, Russell Andrew Lewthwaite, Ian Roger Marsh, David Simon Millan, Manuel Perez Pacheco, David James Rawson, Nunzio Sciammetta, Robert Ian Storer, Paul Anthony Stupple, Nigel Alan Swain, Marcel John De Groot
-
Patent number: 8592629Abstract: This invention relates to sulfonamide derivative of formula (I), to their use in medicine, to compositions containing them, to processes for their preparation, and to intermediates used in such processes. These compounds are inhibitors of Nav1.7.Type: GrantFiled: July 11, 2011Date of Patent: November 26, 2013Assignee: Pfizer LimitedInventors: Andrew Simon Bell, Alan Daniel Brown, Marcel John De Groot, Russell Andrew Lewthwaite, Ian Roger Marsh, David Simon Millan, Manuel Perez Pacheco, David James Rawson, Nunzio Sciammetta, Robert Ian Storer, Nigel Alan Swain, Steven Matthieu Gaulier
-
Publication number: 20130116285Abstract: The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula 10 (I):(I) or a pharmaceutically acceptable salt thereof, wherein Z, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.Type: ApplicationFiled: July 6, 2011Publication date: May 9, 2013Applicant: Pfizer LimitedInventors: Andrew Simon Bell, Alan Daniel Brown, Russell Andrew Lewthwaite, Manuel Perez-Pacheco, David James Rawson, Robert Ian Storer, Nigel Alan Swain
-
Publication number: 20120136023Abstract: The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.Type: ApplicationFiled: November 14, 2011Publication date: May 31, 2012Inventors: Andrew Simon Bell, Iain Brian Gardner, Karl Richard Gibson, David Cameron Pryde, Florian Michel Wakenhut
-
Patent number: 8097621Abstract: This invention relates to compounds of formula (I)Type: GrantFiled: June 10, 2009Date of Patent: January 17, 2012Assignee: Pfizer Inc.Inventors: Andrew Simon Bell, David Graham Brown, Kevin Dack, David Nathan Abraham Fox, Ian Roger Marsh, Andrew Ian Morrell, Michael John Palmer, Carol Ann Winslow
-
Publication number: 20120010207Abstract: The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein Ar1, X, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.Type: ApplicationFiled: July 11, 2011Publication date: January 12, 2012Applicant: PFIZER LIMITEDInventors: Andrew Simon Bell, Alan Daniel Brown, Russell Andrew Lewthwaite, Ian Roger Marsh, David Simon Millan, Manuel Perez Pacheco, David James Rawson, Nunzio Sciammetta, Robert Ian Storer, Paul Anthony Stupple, Nigel Alan Swain, Marcel John De Groot
-
Publication number: 20120010183Abstract: The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein Het1, X, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.Type: ApplicationFiled: July 11, 2011Publication date: January 12, 2012Applicant: PFIZER LIMITEDInventors: Andrew Simon Bell, Alan Daniel Brown, Marcel John De Groot, Russell Andrew Lewthwaite, Ian Roger Marsh, David Simon Millan, Manuel Perez Pacheco, David James Rawson, Nunzio Sciammetta, Robert Ian Storer, Nigel Alan Swain, Steven Matthieu Gaulier
-
Patent number: 7943628Abstract: A compound of Formula (I): or a pharmaceutically and/or veterinarily acceptable derivative thereof, wherein R1, R2, R3, R4, R5, and R8 are as defined above.Type: GrantFiled: December 15, 2006Date of Patent: May 17, 2011Assignee: Pfizer LimitedInventors: Andrew Simon Bell, Charlotte Alice Louise Lane, Charles Eric Mowbray
-
Patent number: 7902195Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R2, R6A, R6B and R8 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, synthetic methods, and intermediates are also disclosed.Type: GrantFiled: April 20, 2007Date of Patent: March 8, 2011Assignee: Pharmacia & Upjohn Company LLCInventors: Robert O Hughes, Andrew Simon Bell, David Graham Brown, Dafydd Owen, Michael John Palmer, Christopher Phillips, David L. Brown, Yvette M. Fobian, John N. Freskos, Steven E. Heasley, E. Jon Jacobsen, Todd Maddux, Brent Mischke, John M. Molyneaux, Joseph B. Moon, D. Joseph Rogier, Jr., Michael B. Tollefson, John K. Walker
-
Publication number: 20090270435Abstract: The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating mammals suffering from the condition of being overweight.Type: ApplicationFiled: November 16, 2007Publication date: October 29, 2009Inventors: Jeffrey Wayne Corbett, Richard Louis Elliott, Andrew Simon Bell
